US EditionPublished • loading... • Updated
After Pfizer or Roche, Astrazeneca Spends $1.2 Billion to Expand Its Obesity Treatment Pipeline
Summary by usinenouvelle.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
In particular, the laboratory recovers a compound of a Chinese biotech planned to enter phase I soon, the beginning of clinical evaluation of a new treatment. With this agreement, AstraZeneca hopes to be able to make a place, in the long term, in this coveted market of treatments to lose weight.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
